TrialRheumatology (Oxford, England)2025

Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis.

Julia Kaufman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.